FIELD: chemical technology, pharmacy.
SUBSTANCE: invention relates to an improved method for preparing sertraline hydrochloride form V that possesses the antidepressant effect. Method involves the following steps: (a) dissolving or suspending sertraline mandelate in a protonic solvent or a mixture of protonic solvents; (b) decreasing pH value of solution or suspension by addition of HCl aqueous solution of HCl solution in protonic solvent with addition of water to form a clear solution, and (c) isolation of the sertraline hydrochloride form V. At step (a) solvents from group comprising alcohol, water or their mixtures are chosen as solvents. For example, an alcoholic solvent used in step (a) can be chosen from group comprising methanol, ethanol, n-propyl alcohol, isopropyl alcohol, n-butyl alcohol, tert.-butyl alcohol and isobutyl alcohol or their mixtures but isopropyl alcohol is preferable. The dissolving or suspending step (a) is carried out at heating and/or stirring in solvent at temperature in the range 20-90oC usually. Decreasing the pH value in step (b) is carried out usually up to the range 1-3 preferably. Sertraline hydrochloride form V obtained at step (c) is isolated by cooling the mixture obtained at step (b). Cooling is carried out under natural conditions to room temperature or using mild cooling agents, such as cold water, water, alcohol or their mixtures wherein indicated alcohol is chosen from group comprising monohydric alcohol, dihydric alcohol or their mixtures. Also, invention relates to a method for preparing a pharmaceutical composition with immediate releasing the sertraline hydrochloride form V that involves mixing sertraline hydrochloride form V prepared by cl. 1 having particles size less 20 mcm and in the amount 90% of the total amount of particles, not less, with a pharmaceutically acceptable diluting agent, carrier or carrier. Proposed method provides simplifying the process for preparing the preparation based on decreasing the total amount of steps.
EFFECT: improved preparing method.
14 cl, 4 sch, 2 dwg, 1 tbl
Title | Year | Author | Number |
---|---|---|---|
METHOD OF PRODUCING POLYMORPHS OF SEROTONIN RECAPTURE INHIBITORS (VERSIONS) | 2004 |
|
RU2376279C2 |
FORM IV OF IVABRADINE HYDROCHLORIDE | 2012 |
|
RU2619121C2 |
NEBIVOLOL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, METHOD OF PRODUCING SAID SALTS AND NEBIVOLOL PHARMACEUTICAL COMPOSITIONS | 2005 |
|
RU2378272C2 |
PHENYL AMINO PYRIMIDINE COMPOUND OR POLYMORPH OF SALT THEREOF | 2016 |
|
RU2712226C2 |
POLYMORPHOUS FORM OF LERCANIDIPINE HYDROCHLORIDE AND SYNTHESIS METHOD THEREOF | 2006 |
|
RU2425033C2 |
PHARMACEUTICALLY ACCEPTABLE SALTS OF PYRILINDOLE ENANTIOMERS FOR USE IN MEDICINE | 2014 |
|
RU2706688C2 |
NEW CRYSTAL SOLID COMPOUND OF 3-PHENYL-4-PROPYL-1-(PYRIDINE-2-YL)-1H-PYRAZOL-5-OL HYDROCHLORIDE | 2018 |
|
RU2754255C2 |
POLYMORPHIC FORMS OF MACROCYCLIC HCV INHIBITOR | 2008 |
|
RU2533830C2 |
PREPARATION OF AND FORMULATION COMPRISING A MEK INHIBITOR | 2013 |
|
RU2669391C2 |
CRYSTALLINE SOLVATES OF HYDROCHLORIDE 6-(PIPERIDIN-4-YLOXY)-2H-ISOQUINOLIN-1-ONE | 2012 |
|
RU2619129C2 |
Authors
Dates
2007-11-20—Published
2003-11-03—Filed